News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

Duke Robotics Announces Commercial Launch of IC Drone for High-Voltage Insulator Washing Services

UAS Drone Corp.

Duke Robotics Corp. (OTCQB: DUKR) (formerly known as UAS Drone Corp, OTCQB: USDR) (the “Company” or “Duke Robotics”), a leader in advanced robotics technology and autonomous drone solutions, is pleased to announce the successful completion of the development and official launch of its innovative IC Drone, a first-of-its-kind system for washing high-voltage electric insulators. Following an extensive development phase and successful pilot testing, the IC Drone is now fully operational with the Israel Electric Corporation (IEC) and positioned for deployment with other utility providers worldwide. The IC Drone’s advanced technology provides utility companies with a safer, more efficient, and environmentally sustainable solution for maintaining high-voltage electric infrastructure than the currently available methods. This state-of-the-art, drone-enabled system replaces traditional methods that rely on large, resource-intensive tanker trucks or helicopters, achieving significant water savings and operational cost reductions per insulator or electric pole. Key Features and Benefits of the IC Drone: Enhanced Safety and Precision: Enables high-voltage insulator cleaning with minimal personnel risk and greater precision compared to traditional methods. Environmental Sustainability: Reduces water usage significantly, supporting sustainability initiatives within utility maintenance. Cost-Effective Operations: Cuts operational costs by tens of percent per insulator and simplifies access to remote or difficult-to-reach infrastructure. Yossef Balucka, Chief Executive Officer of Duke Robotics, commented, “The launch of our IC Drone marks an important milestone in our journey to revolutionize utility maintenance. By offering a safer, more efficient, and eco-friendly solution, we believe the IC Drone will create substantial value for utility providers around the world. We look forward to bringing this groundbreaking technology to market and helping companies optimize their operations while prioritizing environmental stewardship.” This IC Drone launch exemplifies Duke Robotics' commitment to leveraging robotics technology to drive innovation across civilian and utility sectors, complementing its existing solutions for military applications. About Duke Robotics Corp. Duke Robotics Corp. (formerly known as UAS Drone Corp) is a forward-thinking company focused on bringing advanced stabilization and autonomous solutions to both military and civilian sectors. Through its wholly owned subsidiary, Duke Robotics Ltd., the company developed TIKAD, an advanced robotic system that enables remote, real-time, and accurate firing of lightweight firearms and weaponry via an unmanned aerial platform (UAV) designed to meet the growing demand for tech solutions in modern warfare. Duke Robotics Ltd. Also developed the IC Drone, a first-of-its-kind robotic, drone-enabled system for cleaning electric utility insulators. The unique system, based on the Company's advanced intellectual property and know-how, integrates algorithms, autonomous systems, and robotic technologies used in mission-critical applications. For more information about Duke Robotics Corp (Previously UAS Drone Corp) please visit www.dukeroboticsys.com or view documents filed with the Securities and Exchange Commission at www.sec.gov. Forward-Looking Statements This press release contains forward-looking statements. Words such as "future" and similar expressions, or future or conditional verbs such as "will," are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs, assumptions, and information currently available to us. For example, we are using forward-looking statements when we discuss the benefits of its IC Drone technology, the potential for global expansion of our IC Drone services, the anticipated demand from utility providers, and the potential future growth of our commercial offerings. Our actual results may differ materially from those expressed or implied due to known or unknown risks and uncertainties. These include, but are not limited to, risks related to the successful market adoption of the IC Drone, continued development and refinement of our technology, fluctuations in foreign currency exchange rates, and competition from technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and any subsequent filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Contact Details Duke Robotics Corp. Yossef Balucka, CEO invest@dukeroboticsys.com ARX | Capital Markets Advisors North American Equities Desk DUKE@arxadvisory.com

November 11, 2024 06:00 AM Eastern Standard Time

Article thumbnail News Release

Avenue Z Launches New Public Affairs Practice to Help Clients Navigate Complexities of Modern Advocacy

Avenue Z

Avenue Z, a media and technology company, today announced the launch of its Public Affairs Group, a multidisciplinary, strategic practice designed to shape client outcomes in public and private advocacy, shareholder activism and ESG, philanthropy and civil society, and regulatory environments. In response to the growing power and control from big media companies and tech companies, Avenue Z’s new Public Affairs Group leverages a blend of communications, media, creative, and technology to affect meaningful change. The company’s approach supports clients to achieve consensus and desired outcomes by connecting highly targeted content to the right audiences at the right time, building trust. “The way the public is gaining information and forming perspectives has changed, and organizations need to engage their audiences across all channels in new ways,” said Nneka Etoniru, Avenue Z’s EVP of Global Brand Strategy and lead of the new Public Affairs Group. “Our solutions are uniquely positioned to help clients achieve lasting influence by guiding them through critical moments, enhancing their public image, and accomplishing their goals.” “Making a quantifiable impact in public affairs, akin to brand marketing or reputation management, requires both human and technology-informed approach,” said Jeffrey Herzog, Avenue Z founder and CEO. “Our strength lies in blending storytelling, media, and data to create influential connections across channels - from the Wall Street Journal to TikTok." Avenue Z’s Public Affairs practice is tailored to serve a diverse range of clients, including: Private Sector: Helping corporations gain consensus among decision-makers and standard bearers, secure contracts and public-private partnerships, and win necessary approval. Public Sector: Assisting municipal, state, and federal agencies with raising awareness, launching public health initiatives, combatting electoral misinformation, and developing educational campaigns across demographics. High-Profile Public Figures: Assisting in navigating public opinion, counter-influencing harassment campaigns, managing crises, and curating strategically engaging online conversations to protect their reputation. Charities and Philanthropies: Supporting non-profits in raising funds, advancing agendas, enhancing prestige, and navigating challenges to maximize organizational impact. Trade Organizations and Industry Groups: Helping industry-specific organizations advocate for their members' interests, inform external audiences on policy impact, and shape public perception of their industry. Along with the practice launch, Avenue Z has released an insightful trends report, offering a deep dive into the latest shifts shaping public policy and communication, helping organizations stay ahead of the curve. Public Affairs Trend Report 2024: Shaping Perception and Driving Outcomes in High-Stakes Environments covers trends impacting key sectors from healthcare to fintech, venture capital, emerging tech, manufacturing, and more. Read the full report, here. Avenue Z’s ability to lead high-stakes special situations is built on a foundation of expertise lasting more than 25 years. The company’s heritage dates back to 1998, when digital visionary and entrepreneur Jeffrey Herzog pioneered search engine marketing and later, sold iCrossing, his first digital media company, to Hearst Magazines for $450 million. Avenue Z is a media and technology company breaking traditional boundaries between marketing, advertising and PR to increase client revenue and elevate their reputation. From the Wall Street Journal to TikTok, PR to social and search, we create narratives that drive commerce, connections, and conversion, across all channels. With experts, tech and teams based in New York, Orlando, Miami and global reach - we drive influence. Visit www.avenuez.com Contact Details Avenue Z Rachael Zahn +1 407-637-2833 press@avenuez.com Company Website https://www.avenuez.com/

October 30, 2024 07:48 AM Eastern Daylight Time

Article thumbnail News Release

Greg Olsen's Youth Inc. Expands with New Podcast Season and Upcoming Commerce Platform

Youth Inc.

Youth Inc., the first digital media network dedicated exclusively to youth sports content and commerce, today announced that Season Two of its popular Youth Inc. Podcast will launch on Wednesday, Oct. 30. Following the company’s 2024 $4.5 million seed funding round, led by Will Ventures, Youth Inc. is developing a new centralized hub blending news, original content, and retail for the youth sports market. Launched in 2022, Season One of the Youth Inc. Podcast featured conversations with iconic athletes like Jerry Rice, Russell Wilson, Jennie Finch, and Dale Earnhardt Jr. After a breakout debut season with more than 400,000 downloads, millions of impressions, and a nearly perfect viewership rating, Youth Inc. Is expanding its vision as it prepares to launch Season Two. Co-founded by Emmy Award-winning NFL analyst and Pro Bowl tight end Greg Olsen, former Fanatics executive Ryan Baise and Audacy, Inc.’s Tim Murphy, the podcast will feature acclaimed sports psychologist Dr. Michael Gervais as co-host, offering crucial insights for navigating today’s complex youth sports landscape. “While there are more than 30 million young athletes in our country today, there has never been a platform designed to speak directly to families, coaches, and players about the challenges of today’s current state of play,” said Olsen. “Season one taught us invaluable lessons, and we're excited to bring even more insights and depth in Season Two. Partnering with Dr. Gervais, we’ll provide our audience with the tools and knowledge to succeed, all while making the journey engaging and enjoyable." Season Two of the podcast will address the critical challenges young athletes face today including fostering resilience, managing the pressures of competition, and leveraging mindset training for long-term success. The six-episode season is presented by two Founding Partners: Players Health, a sports technology company offering digital risk management services and insurance products to ensure a secure environment for athletes, and MaxU, a cutting-edge platform providing personalized, 24/7 support to help young athletes build skills that enhance their mental performance and overall development. As Youth Inc. enhances its content offerings, it is also set to launch a robust commerce platform in early 2025, designed to further support young athletes and their families. Led by former Fanatics head of new ventures, Ryan Baise, the platform will offer a range of products and services tailored specifically for youth sports families and coaches. "The youth sports landscape is ripe for transformation, and we believe our platform will revolutionize how families access vital information and resources," said Baise. "Our aim is to create a comprehensive marketplace where parents, athletes, and coaches can discover rigorously vetted content and products that reflect the investment they make in their young athletes' futures." To listen to Season One of the Youth Inc. podcast (available on major podcast platforms, YouTube, and social media in both video and audio formats), watch the Season Two trailer or for more information, please visit Youth Inc. Youth Inc. is the first digital media network dedicated exclusively to youth sports content and commerce. Co-founded by NFL alum and Fox Sports broadcaster Greg Olsen, former Fanatics executive, Ryan Baise, and former Audacy and New York Times Co. executive, Tim Murphy, Youth Inc. provides parents, coaches, and athletes with expert-driven guidance and resources to navigate the evolving youth sports landscape. For more information, visit www.youth.inc or follow along on YouTube, Instagram, X, and TikTok. Contact Details Youth Inc. Jackson Gaskins jgaskins@hotpaperlantern.com

October 28, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Players Health Becomes Founding Partner of Greg Olsen’s Youth Inc. to Champion Safety in Youth Sports

Players Health

Players Health, the leading provider of athlete safety and insurance solutions, today announced its partnership as a founding partner with Youth Inc., a content and commerce platform co-founded by NFL alum and Fox Sports broadcaster Greg Olsen. This collaboration marks a significant step toward enhancing safety standards in youth sports through engaging and informative content. It will offer valuable education for athletes, parents, and coaches, while promoting a culture of safety, risk management, and athlete well-being across all levels of play. As digital advertising evolves, and the youth sports industry continues to soar, the growing importance of community-driven strategies and content creation is fueling shifts in the way youth sports organizations engage with their audiences. Through this partnership, Players Health and Youth Inc. will collaboratively generate and distribute content that helps those entrusted with leading youth sports organizations create a safer and more informed environment for young athletes, parents, and coaches. “In today’s rapidly changing youth sports landscape, health and safety must remain at the forefront. Our partnership with Youth Inc. provides a unique opportunity to speak directly to changemakers in our industry and around the country, equipping them with the tools and insights needed to proactively address the challenges facing youth athletes today,” said Tyrre Burks, founder and CEO of Players Health. “Together, we’re not just providing solutions — we’re leading a movement to transform how health and safety is prioritized in youth sports." Youth Inc. provides content across all media platforms, including full-length video/audio podcasts available on YouTube, Spotify, and Apple Podcasts. The network also shares clips on Instagram, Facebook, TikTok, LinkedIn and X. Featuring interviews with some of the biggest stars and thought leaders in the sports world, Youth Inc. serves as a vital resource for navigating the complexities of youth sports today. "Youth sports should be a place where kids can grow, learn, and have fun, and that starts with creating a safe environment. Through our partnership with Players Health, we’re able to provide families and organizations with expert-driven content and resources to help navigate the challenges of today’s youth sports landscape,” said Olsen. “Our shared vision is to equip everyone involved with the knowledge and support they need to foster a safer, more positive experience for young athletes." Season two of Youth Inc. launches on Wednesday, October 30th with six new episodes. Fans, coaches, parents and young athletes can look forward to deeper conversations with top athletes, coaches, and experts in youth sports, as well as valuable advice on safety, well-being, and athletic development. This season promises to bring more exclusive content, further solidifying Players Health and Youth Inc.'s roles as a leading voice in youth sports education. The trailer for Youth Inc.’s upcoming season, featuring Players Health, Greg Olsen, and renowned sports psychologist Dr. Michael Gervais, offers a glimpse into the impactful conversations and expert commentary that will shape the future of youth sports safety and development. To learn more, visit: https://www.playershealth.com/ About Players Health Players Health is a sports technology company providing digital risk management services, reporting tools and insurance products to sports organizations to empower them to stay ahead of their ever-changing safety and compliance responsibilities. Working towards establishing the safest environment for athletes, Players Health views the health and safety of athletes as a priority in today's sports landscape. About Youth Inc. Youth Inc. is the first digital media network dedicated exclusively to youth sports content and commerce. Co-founded by NFL alum and Fox Sports broadcaster Greg Olsen, Youth Inc. provides parents, coaches, and athletes with expert-driven guidance and resources to navigate the evolving youth sports landscape. For more information, visit www.youth.inc or follow along on YouTube, X, and TikTok. Contact Details Players Health Jackson Gaskins playershealth@hotpaperlantern.com Company Website https://www.playershealth.com

October 21, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Article thumbnail News Release

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

VOESH New York Launches New 28 oz. Vegan Hand & Body Crème Collection

VOESH New York

VOESH New York is debuting a new 28 oz. Vegan Hand & Body Crème Collection, created to provide salon clients with a luxurious and healthier hydration experience. These larger bottles offer the same high-quality, vegan-friendly ingredients that have established VOESH as a leader in the body care industry. “We’re thrilled about the addition of these generously sized lotions to VOESH’s product line,” said Tom Harrison, Principal of Coleman Harrison. “VOESH consistently outshines the competition with expert formulas. This new size will undoubtedly enhance manicure and pedicure services, delivering superior results for both clients and technicians.” “As a bonus, technicians can pair these lotions with VOESH’s best-selling Pedi in a Box products,” added Kendall Stone, Principal of Jay Stone Sales. Enriched with 94+% natural-origin ingredients, VOESH’s 28 oz. crèmes are formulated with organic virgin olive oil and natural extracts. They are infused with 100% vegan, clean, and certified organic components and are free from parabens, phthalates, gluten, mineral oil, and more than 1,680 other potentially harmful substances. The velvety texture provides long-lasting moisture and a radiant glow without a greasy feel. These larger bottles not only provide a superior experience but also ensure lasting hydration and value. “Our lotions have always been a best-seller, so we’ve brought them back in a more convenient size for salons,” said Joseph Choi, Co-Founder of VOESH New York. “Salon owners have been asking for our popular massage butter in a bottle, and we’re ecstatic to fulfill this request.” The new collection is available in five delightful scents: Olive Sensation, Lavender Relieve, Vitamin Recharge, Jasmine Soothe, and Green Tea Detox. Each scent is made with premium, IFRA-certified fragrances that pair perfectly with VOESH’s best-selling Pedi in a Box Deluxe 4 Step pedicure kits. This allows for a cohesive pampering experience that caters to clients’ preferences. With a transparent ingredient list, dermatologist testing, and U.S. FDA registration, VOESH’s new 28 oz. Vegan Hand & Body Crèmes are the best addition to guarantee clients and technicians feel good about what goes on their skin. For more information about VOESH’s new 28 oz. Vegan Hand & Body Crèmes, please visit voeshpro.com. About VOESH New York: Founded in 2013, VOESH New York has emerged as a premier destination for clean and efficacious body care solutions catering to head-to-toe wellness. Noteworthy products include Pedi in a Box, Mani in a Box, the award-winning Shower & Empower Vitamin C Shower Filter, and Collagen Gloves and Socks. VOESH New York is committed to providing 100% vegan, cruelty-free, and sustainable products because every body deserves better beauty! All VOESH New York products are certified by PETA and registered with the US Mocra, EU CPNP and UK SCPN, maintaining vegan, cruelty-free, and dermatologist-tested standards. VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. For more information, visit VOESH New York’s website at Voesh.com or contact press@voesh.com. All VOESH New York products are certified by PETA and registered with the EU CPNP, and UK SCPN. Always vegan, cruelty-free, and dermatologist-tested, VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. Contact Details Colleen Mathis +1 917-690-5560 Colleen@absoluterrelations.com Company Website https://voesh.com/

September 06, 2024 08:00 AM Eastern Daylight Time

12345 ... 63